Unlike with the transient silencing, stable silencing of Akt2 strongly inhibited LNM35 tumor growth (532 mm3 +/−188, **P < 0.01) in comparison with control-shRNA (3431 mm3 +/−725) (Fig. 4B). The gene discussed is AKT2; the disease is neoplasm.